# Phase 5 Progress Report
## Virtual Perturbation Screening Pipeline: Scale Up + Figures + Drug Repurposing

### Overall Status: IN PROGRESS ⚡
**Timestamp**: 2026-02-13 18:51 GMT+1

---

## Task 1: Scale to 1000 Cells ⏳ RUNNING
**Status**: Currently processing 800 additional cells (combining with 200 from Phase 4)

### Progress Details:
- **Phase 4 baseline**: 200 cells, 1741 perturbations ✅ COMPLETE
- **Current run**: Processing cells 200-999 (800 additional cells)
- **Progress**: ~30/800 cells processed (4% complete)
- **Estimated completion**: ~80 minutes at current rate
- **Intermediate results**: First batch (25 cells) saved ✅

### Technical Settings Applied:
- ✅ Python environment: `C:\Users\Agent\miniconda3\envs\bioinfo\python.exe`
- ✅ PYTHONIOENCODING=utf-8 set for Windows compatibility
- ✅ BATCH_SIZE=25, N_PERMUTATIONS=30 for memory management
- ✅ GPU: RTX 2060 with CUDA working
- ✅ No emoji in print statements (Windows cp1252 fix)
- ✅ Intermediate saves every 25 cells
- ✅ Phase 4 results loaded for combination

### Expected Outcome:
- Combined dataset: 1000+ cells total
- Improved statistical power (FDR < 0.67)
- Enhanced cell-type specific analysis

---

## Task 2: Publication-Quality Figures ✅ READY
**Status**: Scripts prepared and tested

### Figure Generation Pipeline:
- ✅ **Script created**: `generate_publication_figures.py`
- ✅ **Test successful**: Validated with Phase 4 data
- ✅ **Output directory**: `D:/openclaw/intelligence-augmentation/analysis/results/phase5/figures/`

### Planned Figures:
1. **Figure A**: Heatmap (gene × cell_type mean perturbation effect, clustered)
2. **Figure B**: Ranked bar chart (genes by effect size, 95% CI, significance stars)
3. **Figure C**: Volcano plot (effect size vs -log10(FDR p-value))
4. **Figure D**: Top 5 genes cell-type profiles (grouped bar chart)

### Technical Specifications:
- ✅ matplotlib + seaborn professional styling
- ✅ 300 DPI PNG + PDF output formats
- ✅ Publication-ready formatting
- ✅ Hierarchical clustering for heatmap
- ✅ Statistical significance indicators

---

## Task 3: Drug Repurposing Analysis ✅ COMPLETE
**Status**: Successfully completed with Phase 4 data

### Key Results:
- **Total drug candidates**: 787 compounds
- **Unique drugs**: 741 compounds  
- **Genes with drug targets**: 12/22 target genes
- **Priority autism genes with drugs**: 7/10 genes

### Top Drug Target Genes:
1. **SCN1A** (64 drugs) - Sodium channel, epilepsy target
2. **GRIN2B** (33 drugs) - NMDA receptor subunit
3. **APP** (31 drugs) - Amyloid precursor protein
4. **GRIN2A** (29 drugs) - NMDA receptor subunit
5. **CAMK2A** (7 drugs) - Calcium/calmodulin kinase

### Notable Therapeutic Compounds:
- **NMDA modulators**: Memantine, Ketamine, Acamprosate
- **Anti-epileptics**: Felbamate, Ralfinamide
- **Neuroprotective**: Amantadine, Dextromethorphan

### Genes Without Current Drug Targets:
- MEF2C, NEGR1, SHANK3 - High priority autism targets needing drug development

### Output Files:
- ✅ `drug_repurposing_candidates.csv` (787 drug-gene pairs)
- ✅ `gene_drug_target_summary.csv` (summary statistics)

---

## Data Sources Confirmed:
- ✅ **Single-cell data**: `DLPFC_11k.h5ad` (11,202 cells × 32,344 genes)
- ✅ **Geneformer model**: `Geneformer-V1-10M` with token dictionaries
- ✅ **DGIdb interactions**: `interactions.tsv` (98,239 drug-gene interactions)
- ✅ **Phase 4 results**: Combined cell-level and gene statistics

---

## Next Steps:
1. **Monitor Task 1 completion** (~80 minutes remaining)
2. **Generate final 1000-cell statistics** when Task 1 completes
3. **Execute Task 2 figure generation** with 1000-cell data
4. **Update Task 3 drug analysis** with 1000-cell results
5. **Final integration and summary**

---

## Technical Infrastructure Working:
- ✅ CUDA GPU acceleration
- ✅ Geneformer transformer embeddings
- ✅ Windows UTF-8 encoding fixes
- ✅ Memory management (batching + cache clearing)
- ✅ Intermediate result saves (crash recovery)
- ✅ Figure generation pipeline tested

---

## Critical Success Factors Addressed:
- ✅ **Encoding issues**: PYTHONIOENCODING=utf-8 set
- ✅ **Memory management**: 25-cell batches with GPU cache clearing  
- ✅ **Data persistence**: Intermediate saves every 25 cells
- ✅ **Statistical power**: Scaling to 1000 cells for better FDR
- ✅ **Publication quality**: Professional figure specifications
- ✅ **Therapeutic relevance**: Drug repurposing for autism targets

---

**Status Summary**: Phase 5 is executing successfully with Task 3 complete, Task 2 ready, and Task 1 in progress. All critical requirements have been addressed and the pipeline is functioning as designed. Expected full completion within 2 hours.